Our Journey

_
1

2009 – 2010

_
  • Company incorporated
  • Started as a virtual company with a focus on sales distribution of sustainable portfolio of generics in US markets

2011 – 2013

_
  • Developed multiple sales channels through GPOs, wholesalers & pharmacies
  • Acquired wholesaler licenses in all 50 states
  • Ventured into OSD ANDA development through partnerships
2
3

2014 – 2016

_
  • Partnerships with CROs and CDMOs globally for development/ Co- development of ANDAs and in licensing ANDA

2017 – 2019

_
  • R&D Facility in CA for development of General Injectables & 505(b)(2) products
4
5

2020 – 2021

_
  • Portfolio of 25+ Injectables and 505(B)(2) under various stages of development
  • 32+ ANDAs in Market

2022 – 2023

_
  • Initiation of sterile Injectables focused manufacturing facility in CA with capabilities to manufacture various dosage forms
  • Injectables ANDAs ready to launch in 2023
  • Acquisition of new 503B manufacturing facility in los angeles, CA
  • Commisiioned new solid oral (OSD) facility at Pittsburg, CA
6
7

2024-2025

_
  • Completion of sterile injectable facility
  • 13 Granted pattern for Pharma preparations
  • Major joint venture agreement with AI formulation company for long acting injectable including GLP1
Let’s Connect – Fill Out the Inquiry Form